SCHEMBL4967394

SCHEMBL4967394

COc1ccc(C2(C(=O)N[C@@H]3CCN(S(=O)(=O)c4ccccc4)C3)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.60
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
CCR6 P51684 1/20 0.54
MMP2 P08253 1/20 0.52
MMP13 P45452 1/20 0.52
PKM P14618 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
HTT P42858 1/20 0.52
TSHR P16473 1/20 0.49
CYP3A4 P08684 3/20 0.48
CYP1A2 P05177 2/20 0.48
GAA P10253 1/20 0.48
CYP2C19 P33261 1/20 0.48
USP2 O75604 1/20 0.48
CYP2D6 P10635 1/20 0.48
EPHX2 P34913 1/20 0.48
MAPT P10636 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4965681 1.00 ALDH1A1 (0.60) ALDH1A1MEN1KMT2ACCR6MMP2
SCHEMBL4964636 1.00 ALDH1A1 (0.60) ALDH1A1MEN1KMT2ACCR6MMP2
SCHEMBL4962889 0.86 ALDH1A1 (0.63) ALDH1A1MEN1KMT2A
SCHEMBL4962896 0.86 ALDH1A1 (0.63) ALDH1A1MEN1KMT2A
SCHEMBL4971027 0.86 ALDH1A1 (0.63) ALDH1A1MEN1KMT2A
SCHEMBL4966359 0.80 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2USP2EPHX2
SCHEMBL4966350 0.80 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2USP2EPHX2
SCHEMBL6409684 0.77 HSD11B1 (0.59) ALDH1A1KMT2AMMP2MMP13SMN1; SMN2
SCHEMBL4003536 0.77 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2USP2EPHX2
SCHEMBL4003532 0.77 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2USP2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US claimed
EP-1773780-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP disclosed
EP-1773780-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-04-18 EP disclosed
WO-2006012227-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO disclosed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288338-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 ALDH1A1 345/4885MEN1 365/4885KMT2A 3525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.